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Advanced Staging Procedures Promote
Survival in Patients with Hodgkin's Disease
Before 1950, almost all patients with Hodgkin's disease died
within five years of onset of disease. Today, approximately 70% to
75% of the patients meet the criteria for cure. Advanced staging
procedures and discovery of progressively more effective treatments are responsible for this improvement. Both play key roles
in the management of Hodgkin's disease at UT MDAH, according
to Fredrick B. Hagemeister, MD, Department of Internal Medicine.
The complex natural history of Hodgkin's disease may produce
a number of variables that c~mplicate staging and treatment. This
malignant lymphoma, identified by the presence of Reed-Sternberg cells, usually begins as a unifocal involvement of a cervical
or retroperitoneal lymph node. The disease may spread to other
nodal groups through normal lymphatic channels, although exact
means of dissemination are unclear. If uninterrupted, Hodgkin's
disease may metastasize to the spleen, bone, bone marrow, liver,
lungs, or other organs.
Determination of extent of disease is a primary concern of
internists and radiotherapists at UT MDAH, who base treatment
on disease stage, according to Dr Hagemeister. Because Hodgkin's disease may appear in diverse sites, each patient undergoes an extensive staging workup, including a detailed medical
history and physical examination to detect outward signs of
disease-fever, night sweats, pruritus, and more than 10%
weight loss, as well as palpable, enlarged lymph nodes. Other
procedures, including complete blood counts, blood chemistry
tests, chest roentgenography, liver function tests, and liverspleen scans, reveal evidence of early asymptomatic disease.

Lymphangiography initially is used to determine the extent of
abdominal nodal disease. If results of lymphangiography are
abnormal, no further testing for abdominal nodal disease is
necessary.
Laparotomy is performed for all patients with normal abdominal
lymphangiogram results, except for those with minimal nodal
disease in the high upper neck or inguinal regions only, because
these patients may have more extensive disease than is clinically
or radiographically evident. Biopsies of the liver, abdominal
nodes, and bone marrow, as well as splenectomy, are performed
at the time of laparotomy to detect extranodal disease as well as
nodal involvement not found by lymphangiography.
Based on these staging procedures, appropriate treatment can
be selected. Radiation alone has proved to be effective for
treatment of stage I disease-involvement of one lymph node
above or below the diaphragm-and most of stage II diseaseinvolvement of more than one lymph node on one side of the
diaphragm. More extensive disease is difficult to control with
radiation alone; therefore, at UT MDAH a combination of chemotherapy and radiation or chemotherapy alone is used for the ·
treatment of stage Ill disease-involvement of lymph nodes
above and below the diaphragm-and stage IV diseaseextranodal involvement in one or more organs, bone, bone
marrow, or skin.
Although stage of disease is the primary indicator of treatment
choice, disease location may complicate this decision. Stages I
and II disease generally appear above the diaphragm and are
Continued on page 2
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Chest x-rays of a young woman with stage IV Hodgkin's disease at initiation of high-dose MOPP chemotherapy and consolidation
irradiation (left) and three years later (right) provide evidence of mediastinal disease regression after treatment.

Hodgkin's Disease
Continued from page 1
controlled with radiation (300o-4000 rad total in four weeks) to
the mantle, comprising the entire mediastinum, neck, and axilla.
The inverted Y field, used in irradiating stages I and II disease
occasionally found below the diaphragm, covers the splenic
pedicle and the celiac, para-aortic, iliac, inguinal, and femoral
nodes. Extensive mediastinal involvement in this group of patients is managed as stage Ill disease.
Patients with stage Ill disease receive two cycles of a
combination of mechlorethamine hydrochloride, vincristine (Oncovin), procarbazine, and prednisone (MOPP). Radiation (20004000 rad in three to four weeks) is then administered to one or
more of the following areas, depending upon disease site:
mantle, upper abdomen, pelvis, and lungs (1200 rad in three
weeks maximum to the lungs). Patients with widely separated
areas of disease in the mediastinum and pelvis receive the same
treatment as those with stage IV disease.
Chemotherapy alone is used to control stage IV disease. The
vital organs involved at this stage of disease cannot tolerate the
high doses of radiation necessary to arrest the cancer; therefore,
maximum amounts of chemotherapy are administered.
Although results with MOPP have been superior in patients
with one extranodal site of involvement, the required high doses
cause severe complications, including acute leukemia and other
second malignancies, peripheral neuropathy, sterility, and myelosuppression. In addition, MOPP rarely controls disease in patients with more than one involved extranodal site. For these
reasons, other chemotherapy combinations for patients with
stage IV disease are now used.
At UT MDAH, these patients receive a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP)
alternating with Adriamycin, bleomycin, dacarbazine, prednisone,

and lomustine (ABDIC) for approximately eight cycles or for two
to four cycles after achieving complete remission. Although in use
only since 1981, CVPP-ABDIC appears to control stage IV
disease as effectively as MOPP alone without causing severe
complications. In addition, CVPP-ABDIC has exhibited better
control of disease involving more than one extranodal site.
Investigations of other chemotherapeutic regimens for stage IV
disease are ongoing. Methyl GAG, isophosphamide, methotrexate, and etoposide (MIME) is now being evaluated in Hodgkin's
disease patients at UT MDAH who have suffered relapse after
MOPP chemotherapy. Early studies indicate that MIME may be
one of the few effective drug combinations for patients resistant
to MOPP.
The primary concern of physicians at UT MDAH is proper
staging of Hodg~in's disease, according to Dr Hagemeister.
Statistics show that patients with stages I and II disease now
have a 95% cure rate, as opposed to 85% and 50% rates for
patients with stages Ill and IV disease, respectively. These
figures imply that treatment based upon exact staging, which
prevents progression of undetected disease, can dramatically
improve survival.
(Physicians desiring additional information should write or call
Fredrick B. Hagemeister, MD, Department of Internal Medicine,
MDAH Box 77, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030, (713) 792-2860. Hodgkin's disease and other
lymphomas will be the topic of the 27th Annual Clinical Conference, to be held in November 1983. Please see the conference
announcement in this issue for additional information.-ED)
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New Perspectives in
Human Lymphoma
November 9-12, 1983
Shamrock Hilton Hotel
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Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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Implantable Pump Allows Unlimited Treatment
Without Extended Periods of Hospitalization
The use of an implantable pump in patients with hepatic tumors
now allows unlimited drug treatment for these tumors. The
lnfusaid pump, developed at the University of Minnesota, has
been surgically implanted in 12 patients at UT MDAH within the
last year and has proved to be 100% effective in inducing tumor
response.
Until recently, those patients with hepatic tumors who were not
candidates for resection due to extensive disease underwent
repeated percutaneous catheterizations for administration of
chemotherapeutic agents. However, the repetition of these pro
cedures at times induced arterial occlusion, preventing further
treatment. "The beauty of the pump is that it obviates arterial
trauma, allowing the patients to receive an unlimited number of
repeated treatments," according to Yehuda Z. Patt, MD, chief of
the Regional Therapy Service in the Department of Clinical
Immunology and Biologic Therapy, who works with Arthur W.
Boddie, MD, Department of General Surgery, to treat patients
enrolled in the program.
The cylindrical pump, which is implanted in a "pocket" formed
under the skin, measures approximately four inches in diameter
and one inch in depth. It contains a rubber diaphragm with a 50ml capacity, which serves as a fluid reservoir. The pump is
powered by gaseous freon, which at body temperature enters the
liquid phase, creating vapor pressure; it is this constant pressure
of the freon surrounding the reservoir that forces the contents out
through a catheter into the hepatic artery at a steady rate. Access
to the reservoir, for both the administration and withdrawal of
drugs to be infused, is provided through a port in the center of the
pump designed to accept the needle of an ordinary syringe. A
second port, located on the side of the pump, allows drugs not
appropriate for continuous infusion to be injected directly into the
catheter.

All 12 patients at UT MDAH in whom the pump has been
implanted are being treated with fluorodeoxyuridine (FUDR) on a
two-week-on/two-week-off regimen, according to Dr Patt. Follow
ing each two-week period of FUDA administration, bacteriostatic
water is injected into the reservoir for delivery through the
catheter to prevent clotting and blockage, the most frequent
cause of pump failure, occurring in 2% to 3% of patients. With
that type of regimen, he noted, the life of a pump would be
approximately 20 years; at that time, the rubber diaphragm would
become worn. "However," he said, "although a pump could
remain in place for that length of time, we would most probably
remove it when a patient was declared free of disease."
While several other types of portable drug delivery systems
have been developed, such as a pump and IV bag carried
externally in a vest, all have the potential for causing infection at
the site of catheterization, and au· are relatively noticeable.
"Patients often are reluctant to let the world know they are being
treated for cancer; I had one patient tell me that the vest was his
'badge of cancer,' " Dr Patt said. "With the lnfusaid pump,
however, the risk of infection is greatly reduced, and there is
nothing external to indicate that the patient is undergoing
chemotherapy."
Although the patients now have to return to UT MDAH every
two weeks for fluid replacement, use of the new pump obviates
the monthly week-long hospitalizations previously required for
hepatic-tumor chemotherapy, according to Dr Patt. He and his
colleagues have been anxious to free these patients from the
constraints and high costs associated with lengthy, repeated
hospital stays. "We have been reluctant to keep these patients in
the hospital for long periods of time, because such forced
'imprisonment' gets to a person after a while, and nobody is sure
Continued on page 6

Yehuda Z. Patt, MD, exposes the outline of an
implanted pump in a patient undergoing continuous
infusion chemotherapy (left). The pump has two ports,
one leading into a central reservoir for continuous
infusion of a drug and one on the side that provides
direct access to the catheter (above).
Vol. 28, No. 2
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Hypnotherapy Offers Relief from Discomfort
and Anxiety for Receptive Pediatric Patients
by Donna R. Copeland, PhD, Clinical Psychologist, Director of
the Mental Health Division, Department of Pediatrics
In the Department of Pediatrics at UT MDAH, treatment
focuses on all aspects of care, extending beyond the purely
physiologic problems to include emotional and social matters as
well. One of the major problems that must be dealt with when
treating children with cancer is pain-pain associated with
disease and with tests and treatments. Most children undergo
these with admirable stoicism; however, since tests and treatments are administered over a long period of time, most children,
at one time or another, express their discomfort. Those who have
problems coping with pain or anxiety may have difficulties, even
from the beginning, and may possibly suffer long-lasting psychologic effects from the experience.
Members of the Department of Pediatrics take a number of
measures to help children undergoing tests and treatments.
Physicians and nurses prepare the children for the procedures by
explaining their purposes and how they will be conducted. The
staff members are extremely patient, and when it is possible, they
allow the children, within limits, to choose the times of administration. These measures help reduce anxiety. Sometimes a numbing
instrument or medication, such as sedatives and pain relievers, is
prescribed, and it may help as well. However, many children do
not like them because they involve a painful injection. Despite
these measures, many children become tearful and frightened
and require additional assistance.
Hypnosis is now being used by psychologists and other health
care professionals to assist children who must undergo painful
procedures and treatments that make them nauseated or cause
vomiting. The primary mode used in hypnosis is fantasy; with the
mind, the child can re-create sensations, such as the numbness
of Novocain administered by a dentist. One child at UT MDAH, for
instance, used hypnosis to keep her finger numb long enough for
a blood sample to be withdrawn with little discomfort.
Substitution of one sensation for another is a standard technique in hypnosis and one that is tailored to the individual patient.
As an example, this technique was used by a boy incapacitated
with a brain tumor who enjoyed recalling an earlier time when he
could ride his bike freely. One day, he became uncomfortable and
annoyed with the gauze that had been placed in his rectum due to
an unrelenting, painful sore. The suggestion to the child after
hypnotic induction was to substitute the sensation of the bicycle
seat f<;>r that of the gauze and to focus still more on his memories
of riding his bike and the most pleasant sights, sounds, and
sensations he could recall. According to his mother, he spent
much of the afternoon resting quietly, without the anger he had
expressed earlier in the day. It then was suggested to him that he
could recall those memories anytime he liked. The use of
hypnosis for this child demonstrates that it is a powerful "as if"
experience that can be used to alleviate pain and sickness.
Physicians began using hypnosis at the end of the 18th century
when Anton Mesmer's use of it was publicized. During the 19th
4

century, Sigmund Freud reported on its effectiveness in a number
of his studies. However, after that time, the use of hypnosis in
medical treatment declined and was held in disrepute. Until the
last 1O or 20 years, it was considered quackery by those in the
medical profession and by the lay public.
Recently, the value of hypnosis has been documented not only
for the effective reduction of pain but also for controlling body
processes such as appetite increase or decrease, reduction of
nausea and vomiting, and the control of bleeding in individuals
Continued on page 7

The University of Texas
M. D. Anderson Hospital and Tu,mor Institute
at Houston

National Large Bowel
Cancer Project Workshop

1972-1982: A Decade of
Achievements and
Challenges in Large
Bowel Cancer Research
June 23-26, 1983
Four Seasons Hotel Houston Center
Houston, Texas
Chairperson: Anthony J. Mastromarino, PhD, National
Large Bowel Cancer Project
The goals of this workshop include review of significant
progress in large bowel cancer research over the past
decade, evaluation of current research efforts, identification of gaps in critical areas for future investigations, and
the promotion of communication and collaboration among
clinicians and basic scientists who share common research objectives and interests.
For registration information, write or call the National
Large Bowel Cancer Project, HMB Box 210, The University of Texas M. D. Anderson Hospital and Tumor Institute
at Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-3391.
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Leukocyte Interferon Potential Therapy for
Patients with Metastatic Renal Cell Carcinoma·
by Jorge R. Quesada, MD, Department of Clinical Immunology
and Biologic Therapy; David A. Swanson, MD, Department of
Urology; Antonio Tt-indade, MD, Department of Internal Medicine; and Jordan U. Gutterman, MD, Department of Clinical
Immunology and Biologic Therapy
This article is a summary of a paper that first appeared in Cancer
Research 43:940-947, February 1983.

An estimated 17,000 new cases of metastatic renal cell
carcinoma were diagnosed in 1982. Because no effective systemic therapy currently exists, most of these patients will die
within two years of diagnosis. However, in a recent preliminary
study at UT MDAH, partially purified human leukocyte interferon
induced regression of metastatic tumors in some patients with
renal cell carcinoma, demonstrating that it is potentially active
against the disease.
,Nineteen patients with histologically proven diagnoses of
metastatic renal cell carcinoma were entered into the study. At
that time, performance status among the patients ranged from
60% to 100% (Karnofsky scale). The 15 men and 5 women, who
ranged in age from 29 to 75 years, all had undergone nephrectomy with resection of the primary tumor, and all showed
progression of the disease. Of the 17 patients with lung metastasis, 9 had additional skeletal metastasis, and 1 had additional
liver metastasis, while 2 of the 19 patients had retroperitoneal
and peripheral lymph node involvement only. Anticancer therapy
was discontinued at least four weeks prior to entrance in the
study for the 14 patients who had undergone previous treatment;
7 patients had received hormonal therapy, 3 had received
combined chemotherapy and hormonal therapy, 2 had received
chemotherapy and radiotherapy, and 2 patients had received
palliative radiotherapy. Three of these patients had shown prior
objective response to hormonal therapy or chemotherapy, and
one patient had shown an objective response to localized
radiotherapy with no effect on systemic metastasis.
The human interferon used in the study was obtained from the
State Serum Institute, Finnish Red Cross Center, Helsinki,
Finland, and was partially purified to a specific activity of 1x 106
units/mg of protein. All patients received an initial dose of 3x106
units administered daily by intramuscular injection. In an effort to
improve tumor response in several responding patients, the dose
was increased to 18x106 units administered daily or 18x106 or
36 x 106 units administered twice weekly.
Within the study, complete response to interferon therapy was
defined as the disappearance of all clinical evidence of active
tumor for a minimum of four weeks. Partial response was defined
as a 50% or greater decrease in the size of measurable lesions
with no simultaneous increase in the size of any existing lesion or
the development of new lesions. Minor response was defined as
an objective reduction in measurable lesions of more than 25%
but less than 50%. Mixed effect was defined as a 50% or greater
Vol. 28, No. 2

decrease in the size of some lesions with simultaneous increase
in the size of other existing lesions but with the absence of new
lesions. Stable disease was defined as no change in measurable
disease or less than a 25% increase in the size of measurable
lesions with the absence of new lesions. Progressive disease
was defined as an unequivocal increase of more than 25% in the
size of measurable lesions or the appearance of new lesions.

Table '\
Tumor response to partially purified leukocyte interferon in
patients with renal cell carcinoma

No. of patients Percent
Partial response
Minor response
Mixed effects
Stable disease
Progressive disease
Total

5
2
3
2
7

26.0
10.5
16.0
10.5
37.0

19

100.0

--

In the course of the study, five patients (26%) achieved partial
responses, and two (10.5%) achieved minor responses (Table 1);
these seven patients were considered to have responded to
treatment. Of the remaining patients, considered nonresponsive,
three (16%) demonstrated mixed effects, with evidence of
biologic effect with regression of some tumors but progression of
others; two (10.5%) demonstrated stable disease, one for more
than five months and one for more than six; and seven (37%)
showed progressive disease during the study.
Response to treatment was observed at sites of lung metastasis among the seven responsive patients, and mediastinal
masses regressed in two of these patients. The duration of these
responses, which were observed within 30 to 90 days of
treatment, was from 6 months to more than 12 months.
Clinical characteristics of responsive and nonresponsive patients were compared, and it was found that differences in
pretreatment performance status were statistically significant
among patients in these two groups. Five of the seven patients
who responded to interferon treatment had a performance status
of 100%. In contrast, 8 of the 12 nonresponsive patients had a
performance status of 80% or less. Other clinical characteristics
such as age, sex, history of prior therapy, disease-free interval, or
site of tumor involvement were not significantly different among
patients in these two groups. However, it is interesting to note that
4 of the 7 responsive patients had disease-free intervals of more
than 24 months, while 9 of the 12 nonresponsive patients had
metastatic disease at the time of diagnosis or metastasis that
developed within 24 months of diagnosis. Similarly, five of the
responsive patients had lung involvement alone, while in only
Continued on page 6
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that 'more and longer' is indeed better," he said. In the future,
patients or family members may be trained to refill the pump,
reducing the ties with the hospital even further.
Patients with hepatic tumors are not the only possible beneficiaries of the new device. According to Dr Patt, its use is justified
anywhere it is appropriate to give continuous infusion of a
chemotherapeutic agent. "It could be considered for continuous
delivery of a drug into the intracranial cavity for trecltment of a
brain tumor, or it could be used systemically for treatment of
leukemia," he said. "The pump is going to allow us to expand the
horizons of regional therapy."
(Physicians desiring additional information should write or call
Yehuda Z. Patt, MD, Department of Clinical Immunology and
Biologic Therapy, MDAH Box 41, The University of Texas M. D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030, (713) 792-3487.-ED)

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
DEPARTMENT OF PHARMACY

Fifth Annual
Pharmacy Symposium
on
Cancer Chemotherapy
October 3-5, 1983
Shamrock Hilton Hotel
Houston, Texas
Chairperson: William H. Puckett, Jr, MS, MBA, RPh,
Department of Pharmacy
The symposium is designed to present principles of
cancer patient care to the pharmacist and allied health
professional. Areas to be discussed include the chemotherapeutic treatment of cancer, management of the
various complications of the disease, and an update on
the assessment of chemotherapeutic agent exposure.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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three nonresponders was the disease confined to the lungs.
During the first 30 to 60 days of treatment, the median
leukocyte and granulocyte counts in patients with clinical responses were significantly lower when compared with those of
patients who did not respond, with p values of 0.04 and 0.01,
respectively. (All p values of less than 0.05 were considered
statistically significant.) These differences were more apparent
when responding patients were compared with patients with
progressive disease: Responding patients showed median leukocyte and granulocyte counts of 3.5 x 103 and 1. 7 x 1Q3 cells/cu mm,
respectively, while patients with progressive disease showed
median counts of 5.8 x 103 and 3.6 x 103 cells/cu mm, respectively.
Similar findings were obtained when the nadirs of the leukocyte
and granulocyte counts of responding and nonresponding patients were compared. The effects of interferon on the blood
parameters were readily reversible within 24 to 48 hours when
treatment was withheld or stopped.
The results of this study demonstrate that partially purified
human leukocyte interferon can induce regression of metastatic
tumors in patients with renal cell carcinoma. However, it must be
emphasized that this preliminary report included only a small
number of patients, and follow-up has been too short to estimate
the full impact of this investigational treatment on survival and
clinical benefit to patients.
The study revealed an important correlation between antitumor
response and the ability of interferon to induce leukopenia and
granulocytopenia: These effects were seen early in the course of
treatment and suggest that leukocyte- and granulocyte-count
suppression might have a predictive value. The antitumor effects
of interferon also correlated with performance status and probably reflect differences in the tumor load of the patients.
No evidence of a dose-response effect was observed. All
responding patients showed tumor response at a dose of 3x 106
units, and only one patient seemed to benefit from dose
escalation. The question of dose response is being addressed in
an ongoing randomized study using recombinant DNA-produced
leukocyte interferon, the results of which may determine whether
a single species of leukocyte interferon is as active as the
partially purified polyclonal preparation, which may contain other
biologically active molecules.
The antitumor effects of interferon may depend on the biologic
characteristics and heterogeneity of the metastatic tumor. Clinical
observations suggest that relatively well-differentiated, slowgrowing tumors might be more sensitive targets to the antiproliferative effects of this agent. The natural history of metastatic
renal cell carcinoma is quite variable, and pulmonary lesions, in
particular, may have prolonged periods of slow growth rate or
growth arrest. Such biologic behavior may bear relationship to
the sensitivity of renal cell carcinoma to interferon.
(Physicians desiring additional information should write or call
Jorge R. Quesada, MD, Department of Clinical Immunology and
Biologic Therapy, MDAH Box 41, The University of Texas M. D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030 (713) 792-3527.-ED)
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Hypnotherapy .
Continued from page 4
with hemophilia. Contrary to what many expect, pain that is of a
physical origin is more responsive to hypnosis than pain associated with psychologic distress. The explanation for this is that
if a person experiences pain as a result of psychologic conflicts or
needs, there is a psychologic "investment" in keeping the pain:
For instance, the pain might allow the person to receive sympathy
and comfort from others that might not otherwise be obtained.
Similarly, acute pain or pain of recent onset is usually more
amenable to hypnosis than chronic, long-lasting pain that has
acquired psychologic meaning for the patient.
To what extent a person may use hypnosis to alter body
functions and processes is still unknown. Although some claim
that cancer may be cured or its progress slowed by the use of
mind-control techniques, these claims are based on anecdotal
evidence of individual case studies and have not yet been
subjected to rigorous scientific tests. Growing numbers of wellrespected clinicians do agree, however, that those patients who
are able to use hypnosis effectively while undergoing conventional medical treatment have made themselves feel better and
~ave been able to prolong their lives.
For children with cancer, hypnosis may be used to decrease
nausea and vomiting, increase appetite, develop a more positive
self-image, and adapt to a changed life situation. Following is a
case report, illustrating the uses and limitations of hypnosis with
pediatric patients.
CASE REPORT
(The patient's name has been changed to protect her identity.)
Lana was a 10-year-old girl with stage IV Hodgkin's disease.
She was treated for 9 to 1O months at another center but was
referred to UT MDAH after she relapsed. At that time, she was
suffering from sepsis and meningitis. She was treated and
improved; however, a chest x-ray indicated extensive mediastinal
and pulmonary involvement. Subsequently, she was treated with
radiotherapy and chemotherapy, although chemotherapy was
repeatedly interrupted due to myelosuppression and infections.
An autologous bone marrow transplant was performed and was
successful for a time. Two years later, progressive disease
became uncontrollable, and Lana died.
Lana was referred to the Mental Health Division in the
Department of Pediatrics soon after her admission because she
was very depressed, bitter, and resentful. She resisted treatments and tests vociferously. Not only did she resist physically,
but she was skillful in eliciting guilt feelings. She would say to her
parents, "You don't know what it's like to have cancer."
During the initial psychologic assessment, she articulately
expressed her feelings and experiences since the time of her
diagnosis. She expressed anger at the injustice, fear at the
thought of her family abandoning her, shame about the disease,
guilt about having committed a sin for which the disease was
punishment, and guilt over the increased financial and emotional
demands her disease placed on her family. She was puzzled and
angry that the disease had stricken her rather than her cousin,
Vol. 28, No. 2

toward whom she had feelings of rivalry and superiority. Much to
her parents' dismay, she would say she wanted to stop treatment.
Lana's insight into the psychologic effects of cancer and her
ability to verbalize her feelings and describe her problems was
impressive and unusual for someone her age.
Psychologic intervention for Lana consisted of (1) providing a
psychotherapeutic setting for her to vent her frustration and
outrage and (2) relaxation and hypnosis training to help her cope
more effectively with procedures, increase her appetite, and
reestablish emotional stability and a positive self-image. Family
sessions were held periodically to improve family communication
and to provide comfort and reassurance for the parents.
Lana readily responded to psychotherapy and hypnosis. Five
primary therapeutic goals were established, and her symptoms
were addressed using various types of fantasy and suggestions.
The first goal was to develop a more positive self-image: Lana
had expressed guilt about her disease as a result of transgressions she might have committed. Furthermore, she had lost a
number of friends and had not been able to perform as well in
school as she had previously. Thus, her self-esteem was very
low, and she perceived herself as a helpless victim. Guided
fantasy in hypnosis focused on Lana as an active participant in
the company of others (e.g., exploring an underwater cave with
friends). Frequently, the therapist made direct reference during
the trance to her "goodness through and through," her "good
intentions," and her ability to accomplish goals she set for herself.
The second goal was to increase Lana's tolerance of pain. A
finger puncture for blood withdrawal was selected as the first
procedure with which to try hypnotic anesthesia. The procedure
went well, for the most part, and she managed to use hypnotic
anesthesia frequently thereafter. During bone marrow aspirations
and spinal taps, she still felt pain, but her tolerance was increased
and she was much more cooperative.
An increased appetite was the third goal, as Lana was
seriously malnourished when she came to UT MDAH. She
regarded eating as another area in which others controlled her
life. Initially, it was suggested to her to imagine eating her favorite
food with friends and family present. The success of this fantasy
was probably due to her being allowed to select the food for the
meal. Later, when she was again feeling helpless and isolated,
the suggestion was made that she imagine that she and the
therapist were preparing a banquet for friends. Frequently,
images such as this accomplished more than one goal. For
example, this image was intended not only to increase appetite,
but also to increase a sense of mastery and competency and
reduce feelings of loneliness and isolation.
The fourth goal was to reduce Lana's nausea and vomiting.
Probably the most successful hypnotic intervention was in
diminishing this effect of chemotherapy. It was in this area that the
psychotherapist learned that Lana was using autohypnosis. Her
mother reported that after receiving a particularly potent drug,
Lana liked to return home to her t:,ed, above which she had hung
a crystal ball. It was suspended from a string, and she would hit it
with her foot and concentrate on it as a self-induction technique.
The final goal was to help Lana adjust to her chronic illness.
The treatment for cancer involves a long process-in Lana's
case, two and one-half years. During this time, there were long
Continued on page 8
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Hypnotherapy
Continued from page 7
periods of hospitalization and restriction of activities. Lana liked to
travel, but due to the necessity of being near a treatment center
she could not do this. Fantasy "trips" while under hypnosis
helped a great deal in restoring Lana's sense of freedom and
discovery. Furthermore, these trips were refreshing for her and
allowed her to endure long weeks in the hospital.
However, as Lana's disease progressed, her desire to undergo
hypnosis gradually diminished. Two factors may have accounted
for this. One is that Lana very likely had a progressive viral
disease in the central nervous system that affected her capacity
for symbolic thought and fantasy. She showed a number of
organic symptoms toward the end of her life; e.g., confusion,
disorientation, auditory hallucinations, emotional !ability, disturbances in memory, headaches, numbness, and vomiting. This
condition may have been associated with her decreased ability
and interest in engaging in activities involving fantasy.
Second, it has been noted that children who are afraid they are
going to die do not want to go to sleep. Hypnosis, being a dreamlike state, may not be appealing to these children. Lana was
keenly perceptive and so was quite aware of the imminence of
death. She wanted to live and fought to stay alive. For children in
this situation, therefore, hypnosis may increase their fears rather
than provide comfort.
This case report illustrates the role of hypnosis in psychotherapy for the treatment of a variety of symptoms exhibited by
children with cancer. It also points out its limitations. While there
are a number of reported instances in which hypnosis has been
used to ease the dying process, it is also true that some children
who are fighting for their lives find the trance state somewhat
threatening. Nevertheless, for those who are comfortable with it
and develop skill in using it, hypnosis can provide a significant
amount of relief.
(Physicians desiring additional information should write or call
Donna A. Copeland, PhD, Department of Pediatrics, MDAH Box
87, The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 eertner Avenue, Houston, Texas
77030, (713) 792-6635.-ED)
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Dial Access System Offers
Oncology Series
Current information on cancer-related therapeutic and diagnostic techniques is now available to physicians through the
Southern Medical Association's Dial Access System. Originating
in Birmingham, Alabama, the system consists of taped presentations accessible to subscribers through a toll-free telephone line,
used for the request and transmission of the recordings.
Staff members at UT MDAH developed the tapes for the
oncologic discipline of the Dial Access System, with the intent of
providing essential facts regarding a wide range of topics in a
concise, problem-oriented format, according to Program Editor
Joseph T. Painter, MD, vice president for planning and extramural
programs.
As one of eight disciplines currently included in the system, the
oncologic series includes more than 160 tapes, averaging eight
minutes in length, on the diagnosis and treatment of cancer of the
breast, central nervous system, endocrine system, gastrointestinal tract, genitourinary system, female reproductive system,
head, neck, and thorax, as well as Hodgkin's disease, nonHodgkin's lymphoma, melanoma, pediatric neoplasms, softtissue tumors, and tumors of the skeletal system. Thpes also
address the use of chemotherapy, immunology in clinical oncology, diagnostic radiology, special techniques, supportive care,
and rehabilitation.
The Dial Access System, which operates 24 hours a day,
seven days a week, is offered to Southern Medical Association
members at an annual subscription rate of $5.00 and to nonmembers at an annual rate of $25.00. A comprehensive catalog,
containing titles and identification numbers of the tapes in all
eight disciplines, is provided to all subscribers. Continuing
medical education credit is granted for the completion of each
tape.
(Physicians desiring additional information regarding the oncologic section of the system should write or call the Office of the
Vice President for Planning and Extramural Programs, HMB Box
223, The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030, (713) 792-2203. Those wishing to subscribe to the system
should contact the Southern Medical Association, P.O. Box 2446
Birmingham, Alabama 35201, (205) 323-4400.-ED)
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